HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA Comments On Vinpocetine: Health And Wellness Industry News Roundup

This article was originally published in The Rose Sheet

Executive Summary

AHPA argues FDA erred in vinpocetine proposal; and MusclePharm CEO bails out firm again.

You may also be interested in...



Injunction Closes Another Supplement Firm: Health And Wellness Industry News

Mannatech slumps on Americas downturn; MusclePharm navigates bumps in turnaround; kratom recalls updated; and FDA, DoJ shutter another supplement firm

Viehbacher On Before Brands Board: Health And Wellness Industry News Roundup

Viehbacher’s investment group backs start-up supplement firm; Former Starbucks executive joins Jamba Juice as COO; and MusclePharm forecasts turning corner in 2017.

FDA Guidance Makes Vinpocetine Compliant Despite Ban Proposal – NPA

NPA CEO Daniel Fabricant says some vinpocetine product marketers don't realize the ingredient's status as an active moiety of a botanical long used in the food supply, a knowledge gap obscures that FDA is using an extra-regulatory procedure to remove vinpocetine.

Related Content

Topics

UsernamePublicRestriction

Register

RS108684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel